By Colin Kellaher
Agenus Inc. announced on Wednesday that it was planning an IPO of its cell therapy subsidiary MiNK Therapeutics.
The clinical-stage immuno-oncology company in Lexington, Massachusetts said MiNK had filed a confidential draft of an initial public offering with the Securities and Exchange Commission.
Agenus launched MiNK, then known as AgenTus Therapeutics, in 2017 as a subsidiary for its cell therapy business.
Agenus said the number of MiNK shares to sell and the price range for the proposed offer have not yet been determined. It said it assumes the IPO will occur after the SEC’s review process is completed, subject to market conditions.
MiNK’s filing with the SEC is not yet visible to the public as the company used the generally accepted confidential filing provision introduced in 2012 under the Jumpstart Our Business Startups Act.
Write to Colin Kellaher at [email protected]